Results 161 to 170 of about 3,430 (196)
Some of the next articles are maybe not open access.
EFFECT OF NORGESTREL ON CORPUS LUTEUM FUNCTION
BJOG: An International Journal of Obstetrics & Gynaecology, 1972SummaryCorpora lutea were obtained at laparotomy between days 17 and 25 of the menstrual cycle from nine patients who received 75 μg. Norgestrel daily from the first day of the cycle and from six patients not receiving Norgestrel. All of the control patients had normal corpora lutea which contained significant amounts of progesterone and all except one
T K, Mukherjee +3 more
openaire +2 more sources
Improvement of a d-norgestrel-releasing IUD
Contraception, 1977Abstract A d-norgestrel-releasing IUD was introduced into the uterine cavity of-18 healthy women. The carrier material for d-norgestrel was silastic ® attached to the vertical arm of a Nova-T. Two kinds of d-norgestrel IUDs were used, with d-norgestrel-releasing surface areas of 83 mm 2 and 132 mm 2 , respectively.
C.G. Nilsson, T. Luukkainen
openaire +2 more sources
The conversion of -norgestrel-3-oxime-17-acetate to -norgestrel in female rhesus monkeys
Contraception, 1977Abstract Single intragastric 0.5 mg/kg doses of 14 C-d-norgestrel-3-oxime-17-acetate were given to female rhesus monkeys. Rapid absorption was evidenced by peak concentrations of radioactivity in plasma and whole blood within three hours. A multiphasic decline in concentrations of radioactivity then followed.
S F, Sisenwine +3 more
openaire +2 more sources
URINARY METABOLITES OF DL-NORGESTREL IN WOMEN
Acta Endocrinologica, 1973ABSTRACT Urines obtained from women administered the totally synthetic progestational steroid, 14C-dl-norgestrel, were fractionated on DEAE-Sephadex A-25. This anion exchanger separated unchanged norgestrel and ether extractable metabolites (6.5–10.2 % of the urinary radioactivity) as well as neutral, non-extractable metabolites (4.0–12.3 % of ...
S P, Sisenwine +3 more
openaire +2 more sources
An intracervical device releasing norgestrel
1985The concept of the intracervical device (ICD) has been considered since the early 1970s, when it was reasoned that delivery of progestogens locally to the genital tract might overcome some of the problems associated with the oral intake of progestogens on a long-term basis.
M. Elstein, I. D. Nuttall
openaire +1 more source